Spero Therapeutics, Inc. Investment Income, Interest
Spero Therapeutics, Inc. (SPRO) reported Investment Income, Interest of $377.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-12
- Spero Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $377.00K, a 49.05% decline year-over-year.
- Spero Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $336.00K, a 61.11% decline year-over-year.
- Spero Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $376.00K, a 63.42% decline year-over-year.
- Spero Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $532.00K, a 54.99% decline year-over-year.
- Spero Therapeutics, Inc. investment income, interest for fiscal 2025 was $2.51M, a 46.95% decline from fiscal 2024.
- Spero Therapeutics, Inc. investment income, interest for fiscal 2024 was $4.74M, a 20.27% increase from fiscal 2023.
- Spero Therapeutics, Inc. investment income, interest for fiscal 2023 was $3.94M, a 255.97% increase from fiscal 2022.
- Spero Therapeutics, Inc. investment income, interest for fiscal 2022 was $1.11M, a 219.65% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $377.00K 10-Q · filed 2026-08-12 | $713.00K 10-Q · filed 2026-08-12 | $1.09M derived: sum of 3 quarters · filed 2026-08-12 | $1.62M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $336.00K 10-Q · filed 2026-05-13 | $712.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.24M derived: sum of 3 quarters · filed 2026-05-13 | $1.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $908.00K derived: sum of 2 quarters · filed 2026-03-26 | $1.65M derived: sum of 3 quarters · filed 2026-08-12 | $2.51M 10-K · filed 2026-03-26 |
| 2025-09-30 | $532.00K 10-Q · filed 2025-11-13 | $1.27M derived: sum of 2 quarters · filed 2026-08-12 | $2.14M 10-Q · filed 2025-11-13 | $3.16M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $740.00K 10-Q · filed 2026-08-12 | $1.60M 10-Q · filed 2026-08-12 | $2.63M derived: sum of 3 quarters · filed 2026-08-12 | $3.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $864.00K 10-Q · filed 2026-05-13 | $1.89M derived: sum of 2 quarters · filed 2026-05-13 | $3.07M derived: sum of 3 quarters · filed 2026-05-13 | $4.27M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.21M derived: sum of 2 quarters · filed 2026-03-26 | $3.41M derived: sum of 3 quarters · filed 2026-03-26 | $4.74M 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.18M 10-Q · filed 2025-11-13 | $2.38M derived: sum of 2 quarters · filed 2025-11-13 | $3.71M 10-Q · filed 2025-11-13 | $4.75M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.20M 10-Q · filed 2025-08-12 | $2.52M 10-Q · filed 2025-08-12 | $3.57M derived: sum of 3 quarters · filed 2025-08-12 | $4.52M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.33M 10-Q · filed 2025-05-13 | $2.37M derived: sum of 2 quarters · filed 2025-05-13 | $3.32M derived: sum of 3 quarters · filed 2025-05-13 | $4.30M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.99M derived: sum of 2 quarters · filed 2025-03-27 | $2.98M derived: sum of 3 quarters · filed 2025-03-27 | $3.94M 10-K · filed 2025-03-27 |
| 2023-09-30 | $950.00K 10-Q · filed 2024-11-14 | $1.93M derived: sum of 2 quarters · filed 2024-11-14 | $2.89M 10-Q · filed 2024-11-14 | $3.61M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $982.00K 10-Q · filed 2024-08-05 | $1.94M 10-Q · filed 2024-08-05 | $2.66M derived: sum of 3 quarters · filed 2024-08-05 | $2.87M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $963.00K 10-Q · filed 2024-05-15 | $1.68M derived: sum of 2 quarters · filed 2024-05-15 | $1.89M derived: sum of 3 quarters · filed 2024-05-15 | $2.00M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $715.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $923.00K derived: sum of 2 quarters · filed 2024-03-13 | $1.03M derived: sum of 3 quarters · filed 2024-03-13 | $1.11M 10-K · filed 2024-03-13 |
| 2022-09-30 | $208.00K 10-Q · filed 2023-11-13 | $319.00K derived: sum of 2 quarters · filed 2023-11-13 | $391.00K 10-Q · filed 2023-11-13 | $467.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $111.00K 10-Q · filed 2023-08-10 | $183.00K 10-Q · filed 2023-08-10 | $259.00K derived: sum of 3 quarters · filed 2023-08-10 | $349.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $72.00K 10-Q · filed 2023-05-11 | $148.00K derived: sum of 2 quarters · filed 2023-05-11 | $238.00K derived: sum of 3 quarters · filed 2023-05-11 | $320.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $166.00K derived: sum of 2 quarters · filed 2023-03-30 | $248.00K derived: sum of 3 quarters · filed 2023-03-30 | $346.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $90.00K 10-Q · filed 2022-11-14 | $172.00K derived: sum of 2 quarters · filed 2022-11-14 | $270.00K 10-Q · filed 2022-11-14 | $319.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $82.00K 10-Q · filed 2022-08-10 | $180.00K 10-Q · filed 2022-08-10 | $229.00K derived: sum of 3 quarters · filed 2022-08-10 | $258.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $98.00K 10-Q · filed 2022-05-16 | $147.00K derived: sum of 2 quarters · filed 2022-05-16 | $176.00K derived: sum of 3 quarters · filed 2022-05-16 | $262.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $78.00K derived: sum of 2 quarters · filed 2022-03-31 | $164.00K derived: sum of 3 quarters · filed 2022-03-31 | $401.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $29.00K 10-Q · filed 2021-11-10 | $115.00K derived: sum of 2 quarters · filed 2021-11-10 | $352.00K 10-Q · filed 2021-11-10 | $672.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $86.00K 10-Q · filed 2021-08-05 | $323.00K 10-Q · filed 2021-08-05 | $643.00K derived: sum of 3 quarters · filed 2021-08-05 | $1.05M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $237.00K 10-Q · filed 2021-05-06 | $557.00K derived: sum of 2 quarters · filed 2021-05-06 | $960.00K derived: sum of 3 quarters · filed 2021-05-06 | $1.33M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $320.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $723.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.09M derived: sum of 3 quarters · filed 2021-03-11 | $1.33M 10-K · filed 2021-03-11 |
| 2019-09-30 | $403.00K 10-Q · filed 2020-11-05 | $770.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.01M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $367.00K 10-Q · filed 2020-08-06 | $606.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $239.00K 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $1.10M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |